Literature DB >> 12859188

Recognition and resistance in TEM beta-lactamase.

Xiaojun Wang1, George Minasov, Jesús Blázquez, Emilia Caselli, Fabio Prati, Brian K Shoichet.   

Abstract

Developing antimicrobials that are less likely to engender resistance has become an important design criterion as more and more drugs fall victim to resistance mutations. One hypothesis is that the more closely an inhibitor resembles a substrate, the more difficult it will be to develop resistant mutations that can at once disfavor the inhibitor and still recognize the substrate. To investigate this hypothesis, 10 transition-state analogues, of greater or lesser similarity to substrates, were tested for inhibition of TEM-1 beta-lactamase, the most widespread resistance enzyme to penicillin antibiotics. The inhibitors were also tested against four characteristic mutant enzymes: TEM-30, TEM-32, TEM-52, and TEM-64. The inhibitor most similar to the substrate, compound 10, was the most potent inhibitor of the WT enzyme, with a K(i) value of 64 nM. Conversely, compound 10 was the most susceptible to the TEM-30 (R244S) mutant, for which inhibition dropped by over 100-fold. The other inhibitors were relatively impervious to the TEM-30 mutant enzyme. To understand recognition and resistance to these transition-state analogues, the structures of four of these inhibitors in complex with TEM-1 were determined by X-ray crystallography. These structures suggest a structural basis for distinguishing inhibitors that mimic the acylation transition state and those that mimic the deacylation transition state; they also suggest how TEM-30 reduces the affinity of compound 10. In cell culture, this inhibitor reversed the resistance of bacteria to ampicillin, reducing minimum inhibitory concentrations of this penicillin by between 4- and 64-fold, depending on the strain of bacteria. Notwithstanding this activity, the resistance of TEM-30, which is already extant in the clinic, suggests that there can be resistance liabilities with substrate-based design.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12859188     DOI: 10.1021/bi034242y

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.

Authors:  Jodi M Thomson; Fabio Prati; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo.

Authors:  Oliv Eidam; Chiara Romagnoli; Guillaume Dalmasso; Sarah Barelier; Emilia Caselli; Richard Bonnet; Brian K Shoichet; Fabio Prati
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-05       Impact factor: 11.205

3.  Molecular dynamics of class A β-lactamases-effects of substrate binding.

Authors:  Olivier Fisette; Stéphane Gagné; Patrick Lagüe
Journal:  Biophys J       Date:  2012-10-16       Impact factor: 4.033

4.  Structure-based approach for identification of novel phenylboronic acids as serine-β-lactamase inhibitors.

Authors:  Jacopo Sgrignani; Filomena De Luca; Hayarpi Torosyan; Jean-Denis Docquier; Da Duan; Beatrice Novati; Fabio Prati; Giorgio Colombo; Giovanni Grazioso
Journal:  J Comput Aided Mol Des       Date:  2016-09-08       Impact factor: 3.686

5.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

6.  Label-free fiber optic optrode for the detection of class C β-lactamases expressed by drug resistant bacteria.

Authors:  Simona Zuppolini; Giuseppe Quero; Marco Consales; Laura Diodato; Patrizio Vaiano; Alberto Venturelli; Matteo Santucci; Francesca Spyrakis; Maria P Costi; Michele Giordano; Antonello Cutolo; Andrea Cusano; Anna Borriello
Journal:  Biomed Opt Express       Date:  2017-10-23       Impact factor: 3.732

7.  Click Chemistry in Lead Optimization of Boronic Acids as β-Lactamase Inhibitors.

Authors:  Emilia Caselli; Chiara Romagnoli; Roza Vahabi; Magdalena A Taracila; Robert A Bonomo; Fabio Prati
Journal:  J Med Chem       Date:  2015-07-10       Impact factor: 7.446

Review 8.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

9.  Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Authors:  Andrea Endimiani; Yohei Doi; Christopher R Bethel; Magdalena Taracila; Jennifer M Adams-Haduch; Alexandra O'Keefe; Andrea M Hujer; David L Paterson; Marion J Skalweit; Malcolm G P Page; Sarah M Drawz; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

10.  Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.

Authors:  Sarah M Drawz; Maja Babic; Christopher R Bethel; Magda Taracila; Anne M Distler; Claudia Ori; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.